Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.9K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.9K
Liver Regeneration01:24

Liver Regeneration

4.0K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.0K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.7K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

973
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
973

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activated hepatic stellate cells impair NK cell anti-fibrosis capacity through a TGF-β-dependent emperipolesis in HBV cirrhotic patients.

Scientific reports·2017
Same author

Concurrent agglomeration and straining govern the transport of <sup>14</sup>C-labeled few-layer graphene in saturated porous media.

Water research·2017
Same author

Effects of temperature on graphene oxide deposition and transport in saturated porous media.

Journal of hazardous materials·2017
Same author

Computational Analysis of Intra-Ventricular Flow Pattern Under Partial and Full Support of BJUT-II VAD.

Medical science monitor : international medical journal of experimental and clinical research·2017
Same author

Inflammation is independent of steatosis in a murine model of steatohepatitis.

Hepatology (Baltimore, Md.)·2017
Same author

Electromagnetic pulsed thermography for natural cracks inspection.

Scientific reports·2017

Related Experiment Video

Updated: Dec 9, 2025

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

9.2K

Interleukin-22 in alcoholic hepatitis and beyond.

Xiaogang Xiang1,2, Seonghwan Hwang2, Dechun Feng2

  • 1Department of Infectious Diseases, Translational Laboratory of Liver Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.

Hepatology International
|September 6, 2020
PubMed
Summary

Interleukin-22 (IL-22) shows promise in treating severe alcoholic hepatitis (AH), a dangerous liver condition. Clinical trials suggest IL-22 offers protective benefits against liver injury and may improve outcomes for AH patients.

Keywords:
Acute-on-chronic liver failureAlcoholic liver diseaseInflammationLiver regenerationNonalcoholic steatohepatitis

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.3K
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

14.9K

Related Experiment Videos

Last Updated: Dec 9, 2025

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

9.2K
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.3K
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

14.9K

Area of Science:

  • Hepatology
  • Immunology
  • Gastroenterology

Background:

  • Alcoholic hepatitis (AH) is a severe liver disease with high mortality.
  • Current treatments for AH are limited, with no new drugs developed in decades.
  • Pathogenesis involves inflammation, hepatocyte death, and impaired regeneration.

Purpose of the Study:

  • To review the biology and therapeutic potential of interleukin-22 (IL-22) for alcoholic hepatitis.
  • To explore IL-22's protective roles in preclinical models of liver injury.
  • To discuss the clinical trial outcomes of IL-22 in AH patients.

Main Methods:

  • Review of preclinical models including chronic-plus-binge ethanol feeding and acute-on-chronic liver failure.
  • Analysis of IL-22's functions: anti-apoptosis, anti-fibrosis, anti-oxidation, anti-bacterial, and regenerative stimulation.
  • Examination of clinical trial data for IL-22 treatment in AH.

Main Results:

  • IL-22 demonstrated protective effects against liver injury in various preclinical models.
  • IL-22 exhibits anti-apoptotic, anti-fibrotic, anti-oxidative, and regenerative properties.
  • Clinical trials indicated promising benefits of IL-22 for AH patients.

Conclusions:

  • IL-22 is a potential therapeutic agent for alcoholic hepatitis.
  • Further clinical investigation of IL-22 is warranted for AH treatment.
  • Targeting IL-22 pathways may offer new therapeutic strategies for liver disease.